Cell Cycle

Cell cycle is the entire process of cell division from the completion of one division to the end of the next division and is divided into two phases: interphase and division. Life is a continuous process passed from generation to generation and is therefore a process of constant renewal and starting from scratch. Thus, it is a process of constant renewal and starting from scratch. The life of a cell begins with the division of its parent cell and ends with the formation of its daughter cells, or the death of the cell itself. Usually, the formation of daughter cells is considered to mark the end of cell division. The cell cycle is the process from the formation of daughter cells at one cell division to the formation of daughter cells at the next cell division. During this process, the genetic material of the cell is copied and distributed equally to the two daughter cells.

Cat. No.	Product name
BP13089	CBFβ Inhibitor
BP13089	CBFβ Inhibitor is a cell-permeable CBFβ inhibitor and inhibits its association with Runx1.
BP13090	CBP/p300-IN-2
BP13090	CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc) extracted from patent WO2017205538A1 (example 25).
BP13091	CC-671
BP13091	CC-671 is a dual TTK protein kinase (IC50: 0.005 μM) /CLK2 (IC50: 0.006 μM) inhibitor.
BP13092	CCG-100602
BP13092	CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells (IC50 :9.8 μM).
BP13093	CCG-203971
BP13093	CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. This compound also inhibits PC-3 cell migration (IC50: 4.2 μM), as determined by a scratch wound assay. CCG-203971 causes no cytotoxicity when evaluated by the WST-1 assay. It is well tolerated in normal mice up to doses of 100 mg/kg given intraperitoneally over five days.
BP13094	CCG-222740
BP13094	CCG-222740 is an inhibitor of Rho/MRTF pathway
BP13095	CCT129202
BP13095	CCT129202 is an ATP-competitive pan-Aurora inhibitor for Aurora A, Aurora B and Aurora C with IC50 of 0.042 μM, 0.198 μM and 0.227 μM, respectively. It is less potent to FGFR3, GSK3β, PDGFRβ, etc.
BP13096	CCT241533 hydrochloride
BP13096	CCT241533 hydrochloride is an effective and selective ATP competitive inhibitor of CHK2 (Ki: 1.16 nM; IC50: 3 nM).
BP13097	CCT241533
BP13097	CCT241533 is an effective and selective ATP competitive inhibitor of CHK2 (Ki: 1.16 nM; IC50: 3 nM).
BP13098	CCT244747
BP13098	CCT244747 is a CHK1 inhibitor (IC50: 7.7 nM) and also abrogates G2 checkpoint (IC50: 29 nM).
BP13099	CCT245737
BP13099	CCT245737 is an orally active and selective Chk1 inhibitor (IC50: 1.3 nM); CCT245737 shows much less activity against Chk2 (IC50: 2440 nM).
BP13100	CCT-251921
BP13100	CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor (IC50: 2.3 nM).
BP13101	Cdc7-IN-1
BP13101	Cdc7-IN-1 is a highly selective and ATP competitive inhibitor of Cdc7 kinase (IC50: 0.6 nM at 1 mM ATP). It potently inhibits Cdc7 activity in cancer cells and effectively induces cell death.
BP13102	Cdk1/2 Inhibitor III
BP13102	Cdk1/2 Inhibitor III is a selective Cdk1/2 inhibitor (IC50: 2.1 μM for CDK1/cyclin B).
BP13103	CDK12-IN-2
BP13103	CDK12-IN-2 is an effective and selective inhibitor of CDK12 with an IC50 of 52 nM, >100 μM, >10 μM and 16 μM for CDK12, CDK2, CDK7, and CDK9. CDK12-IN-2 can be used in studies about the function of CDK12.
BP13104	CDK12-IN-3
BP13104	CDK12-IN-3 is a selective CDK12 inhibitor (IC50: 491 nM in an enzymatic assay).
BP13105	CDK12-IN-E9
BP13105	CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and non-covalent CDK9 inhibitor while avoiding ABC transporter-mediated efflux. It has a weak binding ability to CDK7/CyclinH complex (IC50> 1 μM).
BP13106	CDK2-IN-4
BP13106	CDK2-IN-4 is a potent and selective inhibitor of CDK2 with an IC50 of 44 nM for CDK2/cyclin A. It shows 2,000-fold selectivity over CDK1/cyclin B with IC50 of 86 uM.
BP13107	CDK4-IN-1
BP13107	CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.
BP13108	CDK4/6/1 Inhibitor
BP13108	CDK4/6/1 Inhibitor is a CDK4/6 inhibitor (IC50s: 3 and 1 nM).